Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta

Journal of Neuroimmunology
Julia ÅivoMerja Soilu-Hänninen

Abstract

Deficiency of vitamin D is an environmental risk factor for MS. Vitamin D has immunomodulatory effects, including promotion of T-cell differentiation into T-regulatory cells, which produces regulatory cytokines including TGF-β. Increasing serum vitamin D levels have been associated with decreased disease activity in MS patients, but there are only few studies concerning the immunological effects of vitamin D supplementation in MS. In this study we investigated the effect of weekly supplementation of vitamin D3 or placebo on serum levels of multiple cytokines in patients with relapsing remitting MS. The study was conducted on the patient cohort of the Finnish Vitamin D study. All patients were using IFN-beta-1b and were randomized to add-on treatment with either cholecalciferol 20,000 IU/week or placebo. Concentrations of LAP (TGF-β), INF-γ, IL-17A, IL-2, IL-10, IL-9, IL-22, IL-6, IL-13, IL-4, IL-5, IL-1β and TNF-α were determined at screening and at 12 months using commercial fluorescent bead immunoassay kits. LAP (TGF-β) levels increased significantly in the vitamin D treated group from a mean of 47 (SE 11) pg/ml to 55 (SE 14) pg/ml in 12 months (p-value=0.0249). Placebo treatment had no significant effect on LAP levels. The l...Continue Reading

References

Jul 1, 2004·The Journal of Steroid Biochemistry and Molecular Biology·Luciano AdoriniMilan Uskokovic
Jan 8, 2008·Journal of Neuroimmunology·Joost SmoldersRaymond Hupperts
Jan 24, 2008·Nature Clinical Practice. Endocrinology & Metabolism·John S Adams, Martin Hewison
Jul 26, 2008·Multiple Sclerosis : Clinical and Laboratory Research·J SmoldersR Hupperts
Mar 27, 2009·Brain : a Journal of Neurology·Jorge CorrealeMaría Inés Gaitán
May 25, 2010·Lancet Neurology·Alberto AscherioK Claire Simon
Apr 19, 2011·The Journal of Allergy and Clinical Immunology·Angelic M G van der AarEsther C de Jong
Jan 13, 2012·Annals of the New York Academy of Sciences·Michael StassenTobias Bopp
Mar 23, 2012·Immunological Reviews·Joseph A DiDonatoMichael Karin
Mar 30, 2012·Multiple Sclerosis : Clinical and Laboratory Research·Aideen C AllenJean M Fletcher
Aug 21, 2012·European Journal of Immunology·Zoë UrryCatherine M Hawrylowicz
Aug 29, 2012·Annals of Neurology·Ellen M MowryDaniel Pelletier
Jul 10, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Vittorio MartinelliGiancarlo Comi
Jan 22, 2014·JAMA Neurology·Alberto AscherioChristoph Pohl

❮ Previous
Next ❯

Citations

Mar 6, 2016·Journal of Neuroimmunology·Joost SmoldersJan Damoiseaux
Feb 13, 2016·Revue neurologique·G MpandzouM Yahyaoui
Jul 25, 2015·Journal of Experimental & Clinical Cancer Research : CR·Bassem RefaatAthar Khojah
Mar 17, 2019·International Journal of Molecular Sciences·Monika BerezowskaHelen Dawes
Jul 16, 2020·British Journal of Pharmacology·Wei Zhen YehHelmut Butzkueven
Aug 25, 2020·Annals of Clinical and Translational Neurology·Priscilla Bäcker-KoduahAlexander Ulrich Brandt
May 2, 2020·International Journal of Molecular Sciences·Samiksha WasnikXiaolei Tang
Oct 5, 2017·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Karen O'ConnellMichael Hutchinson
Jul 5, 2019·CNS & Neurological Disorders Drug Targets·Javier Caballero-VillarrasoIsaac Túnez
Dec 12, 2019·Frontiers in Immunology·Farhan CyprianGuillermina Girardi
Sep 29, 2020·Frontiers in Neurology·Christopher M DwyerTrevor J Kilpatrick
Nov 7, 2019·CNS Drugs·Joost SmoldersTrygve Holmøy
Jul 20, 2019·Autoimmunity Reviews·Giuseppe MurdacaSebastiano Gangemi
Mar 4, 2021·Journal of Pharmaceutical Health Care and Sciences·Zeinab GhorbaniMansoureh Togha
Jul 3, 2021·Journal of Clinical Medicine·Anna Walawska-HrycekEwa Krzystanek

❮ Previous
Next ❯

Related Concepts

Related Feeds